Eight Biotherapeutics

Eight Biotherapeutics is a pre-clinical stage biotechnology company focused on developing a new class of antibody therapeutics targeting G protein-coupled receptors (GPCRs). The company utilizes its proprietary 8-Bio platform to identify and optimize antibodies that can modulate GPCR signaling with high specificity, addressing challenges that have historically limited the druggability of this target class. Their primary therapeutic focus is on chronic inflammatory diseases, with lead programs aimed at treating inflammatory bowel disease, including ulcerative colitis and Crohn's disease. By leveraging deep expertise in GPCR biology and protein engineering, Eight Biotherapeutics aims to deliver transformative treatments for patients with high unmet medical needs in immunology.